Literature DB >> 28721895

Late Cardiac Toxicity After Mediastinal Radiation Therapy for Hodgkin Lymphoma: Contributions of Coronary Artery and Whole Heart Dose-Volume Variables to Risk Prediction.

Ezra Hahn1, Haiyan Jiang2, Angela Ng3, Shaheena Bashir2, Sameera Ahmed1, Richard Tsang1, Alexander Sun1, Mary Gospodarowicz1, David Hodgson4.   

Abstract

PURPOSE: Mediastinal radiation therapy (RT) for Hodgkin lymphoma (HL) is associated with late cardiotoxicity, but there are limited data to indicate which dosimetric parameters are most valuable for predicting this risk. This study investigated which whole heart dosimetric measurements provide the most information regarding late cardiotoxicity, and whether coronary artery dosimetry was more predictive of this outcome than whole heart dosimetry. METHODS AND MATERIALS: A random sample of 125 HL patients treated with mediastinal RT was selected, and 3-dimensional cardiac dose-volume data were generated from historical plans using validated methods. Cardiac events were determined by linking patients to population-based datasets of inpatient and same-day hospitalizations and same-day procedures. Variables collected for the whole heart and 3 coronary arteries included the following: Dmean, Dmax, Dmin, dose homogeneity, V5, V10, V20, and V30. Multivariable competing risk regression models were generated for the whole heart and coronary arteries.
RESULTS: There were 44 cardiac events documented, of which 70% were ischemic. The best multivariable model included the following covariates: whole heart Dmean (hazard ratio [HR] 1.09, P=.0083), dose homogeneity (HR 0.94, P=.0034), male sex (HR 2.31, P=.014), and age (HR 1.03, P=.0049). When any adverse cardiac event was the outcome, models using coronary artery variables did not perform better than models using whole heart variables. However, in a subanalysis of ischemic cardiac events only, the model using coronary artery variables was superior to the whole heart model and included the following covariates: age (HR 1.05, P<.001), volume of left anterior descending artery receiving 5 Gy (HR 0.98, P=.003), and volume of left circumflex artery receiving 20 Gy (HR 1.03, P<.001).
CONCLUSION: In addition to higher mean heart dose, increasing inhomogeneity in cardiac dose was associated with a greater risk of late cardiac effects. When all types of cardiotoxicity were evaluated, the whole heart variable model outperformed the coronary artery models. However, when events were limited to ischemic cardiotoxicity, the coronary artery-based model was superior.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28721895     DOI: 10.1016/j.ijrobp.2017.03.026

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  30 in total

1.  Residual Site Radiotherapy After Immunochemotherapy in Primary Mediastinal B-Cell Lymphoma: A Monoinstitutional Retrospective Study.

Authors:  Vitaliana DE Sanctis; Alice DI Rocco; Maria Christina Cox; Maurizio Valeriani; Francesca Perrone Congedi; Dimitri Anzellini; Maria Massaro; Gianluca Vullo; Giuseppe Facondo; Flavia DE Giacomo; Marco Alfò; Daniela Prosperi; Patrizia Pizzichini; Sabrina Pelliccia; Agostino Tafuri; Maurizio Martelli; Mattia Falchetto Osti
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

Review 2.  Cardiovascular Toxicities of Radiation Therapy.

Authors:  Gary D Lewis; Andrew Farach
Journal:  Methodist Debakey Cardiovasc J       Date:  2019 Oct-Dec

Review 3.  Cardiotoxicity of radiation therapy in esophageal cancer.

Authors:  Milan Vošmik; Miroslav Hodek; David Buka; Petra Sýkorová; Jakub Grepl; Petr Paluska; Simona Paulíková; Igor Sirák
Journal:  Rep Pract Oncol Radiother       Date:  2020-02-25

4.  Cardiovascular complications after radiotherapy.

Authors:  Izabela Nabiałek-Trojanowska; Ewa Lewicka; Anna Wrona; Anna M Kaleta; Zuzanna Lewicka-Potocka; Grzegorz Raczak; Rafał Dziadziuszko
Journal:  Cardiol J       Date:  2018-10-19       Impact factor: 2.737

Review 5.  Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity.

Authors:  Vivian Y Chang; Jessica J Wang
Journal:  Curr Oncol Rep       Date:  2018-04-30       Impact factor: 5.075

Review 6.  The impact of proton therapy on cardiotoxicity following radiation treatment.

Authors:  Andrew J Frankart; Rajaram Nagarajan; Luke Pater
Journal:  J Thromb Thrombolysis       Date:  2020-10-08       Impact factor: 2.300

7.  Heart V5 predicts cardiac events in unresectable lung cancer patients undergoing chemoradiation.

Authors:  Lisa Ni; Matthew Koshy; Philip Connell; Sean Pitroda; Daniel W Golden; Hania Al-Hallaq; Greg Hubert; Greg Kauffman; Anne McCall; Renuka Malik
Journal:  J Thorac Dis       Date:  2019-06       Impact factor: 2.895

8.  Electrocardiogram-Gated Computed Tomography with Coronary Angiography for Cardiac Substructure Delineation and Sparing in Patients with Mediastinal Lymphomas Treated with Radiation Therapy.

Authors:  Scott C Lester; Kekoa Taparra; Molly M Petersen; Ryan K Funk; Miran J Blanchard; Phillip M Young; Joerg Herrmann; Ashley E Hunzeker; Heather L Schultz; Cynthia McCollough; Alexandria M Tasson; Shuai Leng; James A Martenson; Amanda J Deisher; Thomas J Whitaker; Eric E Williamson; Nadia N Laack
Journal:  Pract Radiat Oncol       Date:  2019-11-26

Review 9.  Cardiotoxicity of mediastinal radiotherapy.

Authors:  Ivica Ratosa; Maja Ivanetic Pantar
Journal:  Rep Pract Oncol Radiother       Date:  2019-10-30

10.  Rationale and early outcomes for the management of thymoma with proton therapy.

Authors:  He J Zhu; Bradford S Hoppe; Stella Flampouri; Debbie Louis; John Pirris; R Charles Nichols; Randal H Henderson; Catherine E Mercado
Journal:  Transl Lung Cancer Res       Date:  2018-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.